Gemcitabine/TS-1 combination chemoradiotherapy for unresectable locally advanced pancreatic cancer(Phase I study)
Phase 1
- Conditions
- nresectable locally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000005042
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1.Active infection 2.Lung fibrosis or intestinal pneumoni detectable on chest X-ray and CT 3.Severe complication (heart disease, cirrhosis, diabetes) 4.Myocardial infarction within 3 months 5.Active synchronous or metachronous malignancy 6.Pregnant or lactation women, or women with known or suspected pregnancy 7.Symptomatic brain metastasis 8.history of severe drug allergy 9.Patients who are judged inappropriate for the entry into the study by the investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Efficacy, Median survival time (MST), Palliative efficacy